


The CTi Token Sale

To distribute CTi tokens for use on Clinical Trial Intelligence, a token sale will be run in 2020. CTi tokens will be generated using the ERC-20 protocol in an Ethereum smart contract. The total maximum contribution amount (hardcap) is set at \$7m USD, of which \$3m will be available in two pre-sales (Tier 1 and Tier 2), and a further \$4m will be offered to the general public on an exchange platform (yet to be announced).

General Information

- CTi is an ERC-20 token on the Ethereum public blockchain.
- The base price of the CTi Token in the main token sale (IEO) will be USD \$0.12c = 1 CTi.
- The total CTi supply to be minted is 2,000,000,000.
- This will make the maximum CTi marketcap in the event of a hard cap sell-out, USD \$24m.
- 16.7% of the total CTi supply will be made available to the public during the main token sale (IEO).
 - A further 13.3% and 10% of the total CTi supply will be made available to partners in the Tier 1 and Tier 2 pre-sale rounds respectively.
- The token sale hardcap is USD \$7m (incl. Pre-sale Rounds).
- The token sale softcap is USD \$2m.
 - In the unlikely event that the softcap target is not reached at the end of the offering, all participants will have their contributions returned. The refund mechanism is part of the design of our TGE smart contract, which is reviewable on the ClinTex Github and Etherscan.io.
- Any unsold tokens from the main public sale round will be burnt.

CTi Distribution Breakdown



Distribution Dates, Bonus's, Lock-ups & Vest

- Public round (IEO) CTi tokens will be tradable immediately on the partner exchange (details TBA).
- Pre-Sale Tier 1 tokens will come with a phased 0–24 month lock-up vest period enforced by smart contract.
- Pre-Sale Tier 2 tokens will come with a phased 0–2 month lock-up vest period enforced by smart contract
- CTi tokens that are distributed to Shareholders and Management Team will all have a 6–48 months lock-up vest enforced by smart contract.
- CTi tokens reserved for Pharmaceutical Industrial Trials & Testing will be locked until full live net launch and will not be in public circulation (reviewable on the ClinTex Github).

Currencies Accepted

ETH (Ethereum), BTC (Bitcoin) and BNB (Binance Coin) will be accepted in the Token Sale.

- The ETH:CTi, BTC:CTi and BNB:CTi values will be determined closer to the time of launch, based on the USD value of those respective cryptocurrencies at that time.
- Fiat currency will also be accepted –EUR, GBP, USD, CHF, RMB & KRW, payable by Visa or MasterCard.
- For the public round, discussions with exchange platforms are on-going and details will be announced as soon as they are available.

Details of the Issuer

The issuer is eClinTexLtd, t/a ClinTex Ltd, a private limited liability company incorporated in Estonia with Company Registration Number: 14991810 and having its registered address at Juhkentali 8, Tallinn 10132, Estonia.

The object of the issuer is to source, verify, collect and operate online data of all kinds and in all fields, including but not limited to clinical data trials, and to operate an online platform for the storage and analysis of such data and to facilitate, enable and aid the availability of such data to its businesses, customers, organisations and other third parties without any restrictions whatsoever.

Who We Work With

STERLING LAW.

Legal Status

The ClinTex CTi whitepaper and CTi token has undergone extensive legal review in relation to the UK's Financial Services and Markets Act 2000 (Regulated Activities).

Our partners at Sterling Law have confirmed the CTi token is not within the regulatory classification is of a 'Security' or 'Financial Instrument', and thus does not fall under the FCA regulatory perimeter.

More information available on request.



SUM & SUBSTANCE

KYC/AML Verification

All Private Round Participants will be required to undergo a whitelisted identification verification process, in line with globally accepted standards of AML/KYC regulation.

Government photo ID will be required as part of the registration process. The CTi TGE KYC/AML verification will be undertaken by our partners, Sum & Substance.

Sum & Substance are a pioneer in the Trusted Digital Identity space that specialise in identity proofing, risk-based authentication, regulatory identification, and the detection and prevention of the use of stolen identities, ensuring a robust and comprehensive risk and compliance solution.

Under legal advice, unfortunately residents and citizens of the USA will not be permitted to register for the CTi token sale at this time - this is under review at current and should it change, we will make the announcement through our social media channels or mailing list.



BEOSIN Blockchain Security

Security & Audit

All CTi TGE smart contracts are deployed by/on behalf of ClinTex Ltd;

All CTi TGE smart contracts are double independently audited for both our participants' security and our own, first internally by our technical advisors and then externally by a third-party;

The CTi TGE smart contract external auditing will be undertaken by Beosin.

Beosin is a well respected and experienced blockchain technology firm offering a full spectrum solution from tactical technical execution to high-level theoretical modelling, with a speciality in the auditing of smart contracts for blockchain projects.

ClinTex's Projected Use of Funds

30%

Platform development (blockchain developers, machine learning and neuro-linguistic programming experts, web and software developers) - building scalability of the Clinical Trials Intelligence to meet demand.

25%

Clinical and analytic development (data scientists, statisticians, etc.) - further enhancing the range of analytics to meet customer demand, and expanding predictive analytics capabilities through integration of data from multiple clinical trials.

15%

Marketing & sales, business growth and development - implementation of ClinTex' marketing strategy to target the uptake of the Clinical Trials Intelligence in the pharmaceutical industry, medicinal and academic settings.

10%

Business Leadership & Management (Board of Directors).

7%

Operational expenses (admin / HR / rent, utilities, etc.).

7%

ClinTex research grants to fund collaboration on clinical trials with NHS trusts, universities and the Institute of Translational medicine

6%

Legal and accounting expenses, monitoring and assurance of compliance to FDA regulations (21 CFR part 11 compliance)

Disclaimer

This document should only be read as an introduction to the CTi Token Sale, and any decision to purchase any token issued by ClinTex should be based on the consideration of the Clinical Trials Intelligence whitepaper as a whole. This document has been created for informative purposes only and does not represent any offer or solicitation to sell financial instruments or units of any collective investment schemes, and any such potential offer or solicitation of financial instruments may only be made by ClinTex by means of a prospectus or other offering documentation in terms of any applicable law. Parties and/or contributors are advised to read this document carefully in full, and

exercise due diligence, as information within this document may evolve to reflect ongoing development of the tools and processes, outputs and lessons learned from pilot projects, feedback from clients, and regulatory and pharmaceutical industry requirements. In the absence of any specific law regulating this document, the persons taking responsibility (the ClinTex team) are bound by civil law and accordingly civil liability is attached to them. This document may be amended periodically without prior warning and any token holders or prospective token holders should ensure that they are reading the most recent version of the document, as made available on the ClinTex website www.clin-tex.io.